Clinical trial
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered…
NCT00220311 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00220311 |
|---|---|
| Title | A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia |
| Official title | A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia… |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic, B-Cell |
| Intervention type | Drug |
| Interventions | Fludarabine Phosphate (Fludara) |
| Enrollment | 10 |
| Start date | Nov 1, 2000 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 4, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: